We therefore tested a pharmacological Rsk inhibitor (BI-D1870) for its ability to inhibit the proliferation of osteosarcoma cells and found that the effects observed by genetic Rsk2 inactivation were mimicked. Here, RPS6KA3 is linked to osteosarcoma.